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Background: The Fat Mass and Obesity-Associated Protein (FTO) gene rs9939609 single nucleotide polymorphism
(SNP) has been associated with obesity, metabolic syndrome, insulin resistance (IR), and type 2 diabetes mellitus in
the general population. The aim of our study was to examine for the first time the association of the rs9939609
polymorphism with metabolic disturbances, liver disease and virologic response to hepatitis C virus (HCV) therapy
with pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV) in human immunodeficiency virus (HIV)/HCV coinfected
patients.
Methods: We carried out a cross-sectional study in 261 patients, of whom 178 were subsequently treated with
pegIFNα/RBV therapy. FTO rs9939609 and IFNL3 rs12980275 polymorphisms were genotyped by GoldenGate®.
The main outcomes were: 1) metabolic disturbances: insulin resistance (homeostatic model assessment (HOMA-IR))
and overweight (body mass index (BMI)); 2) liver disease (Metavir score): significant fibrosis (F ≥2) and steatosis
(>10% fatty hepatocytes); and 3) virologic response to HCV treatment: sustained virologic response (SVR).
Results: The rs9939609 AA genotype was associated with higher values of BMI (adjusted arithmetic mean ratio
(aAMR) = 1.08; 95% confidence interval (95%CI) = 1.03 to 1.14; P = 0.002) and HOMA-IR (aAMR = 1.32; 95%CI = 1.03
to 1.69; P = 0.027). Patients with an rs9939609 AA genotype had higher likelihoods of achieving values of BMI ≥27.5
kg/m2 (adjusted odds ratio (aOR) = 3.46; 95%CI =1.17 to 10.21; P = 0.024), HOMA-IR ≥2.5 (aOR = 2.09; 95%CI = 1.02
to 4.32; P = 0.045), significant fibrosis (aOR = 2.34; 95%CI =1.02 to 5.36; P = 0.045) and steatosis (aOR = 3.65;
95%CI = 1.29 to 10.36; P = 0.015). The rs9939609 AT/AA genotype decreased the likelihood of achieving SVR
(aOR = 0.58; 95%CI = 0.34 to 0.99; P = 0.044). A decision tree was performed with the genotypes of HCV, IFNL3 and FTO.
The incorporation of rs9939609 significantly improves the prediction of SVR (P <0.05). The overall accuracy was 68.2%.
Conclusions: Patients carrying the unfavourable AT/AA genotype of rs9939609 polymorphism had higher odds of
metabolic disturbances and a lower likelihood of achieving successful virologic response to HCV therapy.
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The combination antiretroviral therapy (cART) has made
human immunodeficiency virus (HIV) infection a chronic
manageable disease in high income countries [1]. In this
setting, chronic hepatitis C (CHC) has turned into an im-
portant comorbidity and a major cause of death in HIV/
hepatitis C virus (HCV) coinfected patients [2,3], because
HIV infection accelerates the natural history of CHC
[4-6]. Moreover, although the published data suggest
that cART might be beneficial for HIV/HCV-coinfected
patients [4], the interactions among HIV, HCV and
cART are also associated with several metabolic disorders
[7], including dyslipidaemia, lipodystrophy, steatosis, insu-
lin resistance and type 2 diabetes mellitus [7,8].
For many years, dual therapy with pegylated-interferon-
alpha plus ribavirin (pegIFNα/RBV) has been the standard
anti-HCV therapy for HIV/HCV-coinfected patients [9],
and is still used in combination with new direct-acting
antivirals, such as telaprevir or boceprevir [10]. The rate
of HCV clearance after pegIFNα/RBV therapy is around
20% to 40% for patients infected with HCV genotype 1
(HCV-GT1) and HCV genotype 4 (HCV-GT4), and 50%
to 60% in HCV genotype 2 (HCV-GT2) and HCV geno-
type 3 (HCV-GT3) patients [11,12]. To date, the best
baseline predictors for HCV therapy are HCV genotype,
HCV viremia, liver fibrosis and single-nucleotide polymor-
phisms around the interferon lambda 3 (IFNL3) gene, also
known as interleukin 28B (IL28B) [13]. However, an unex-
plained variability in HCV treatment outcome still re-
mains which suggests that other host genetic factors may
play an important role in pegIFNα/ribavirin therapy [14].
Thus, the identification of predictors for HCV therapy
might help to ensure an adequate selection of the best
candidates and to minimize any undesirable toxicity.
At present, the new direct-acting antivirals (DAAs) are
generally administered in combination with pegIFNα/ri-
bavirin, particularly in difficult-to-treat patients infected
with GT1/4 [15,16]. Moreover, the new IFNα-free regi-
mens with DAAs in combination with or without ribavi-
rin are being developed for difficult-to-treat patients
[17]. However, the potential use of these new DAAs in
HIV/HCV coinfected patients is complicated due to the
choice of patients to treat, potential for drug-drug inter-
actions and overlapping toxicities between HIV and
HCV therapy [16]. In addition, the new DAAs are more
expensive and there are serious restrictions on their
administration, and in many regions in the world these
drugs are inaccessible. In fact, treatment with pegIFNα/
ribavirin remains the only option of therapy for many
patients throughout the world.
The Fat Mass and Obesity-Associated Protein, also
known as FTO, is an alpha-ketoglutarate-dependent diox-
ygenase. The FTO gene plays an important role in the
management of energy homeostasis and the regulation ofbody weight [18]. This gene is located on chromosome
16q12.2 and has nine exons which encode a 2-oxogluta-
rate-dependent nucleic acid demethylase highly conserved
in vertebrates [18]. Single nucleotide polymorphisms
(SNPs) that cluster in the first intron of the FTO gene
were first discovered in a genome-wide association study
(GWAS) for type 2 diabetes mellitus [19], and, subse-
quently, other GWAS reported that the FTO polymor-
phisms were associated with obesity [20]. Evidence from
epidemiological and functional studies suggests that FTO
confers an increased risk of obesity by subtly changing
food intake and preference [21]. The FTO rs9939609 poly-
morphism, one of the SNPs that were reported, has been
associated with obesity [22], metabolic syndrome [23],
insulin resistance [24], type 2 diabetes mellitus [19] and
cardiovascular disease [25].
Considering that obesity, insulin resistance and steatosis
have been identified as important factors that promote
metabolic syndrome progression and failure of HCV ther-
apy in HCV-infected patients [26], the aim of this study
was to examine the association of the FTO rs9939609
polymorphism with the metabolic disturbances and viro-
logic response to HCV therapy with pegIFNα/RBV in
HIV/HCV-coinfected patients.
Methods
Patients and study design
We carried out a cross-sectional study in 261 HIV/HCV-
coinfected patients from Hospital Gregorio Marañón
(Madrid, Spain) between September 2000 and July 2009.
In addition, we performed a retrospective study in 178 of
them who started HCV treatment.
All subjects included in our study were European
white and HCV treatment-naive patients, who were
potential candidates for HCV therapy and, in most cases,
underwent a liver biopsy. The inclusion criteria were: de-
tectable HCV-RNA by polymerase chain reaction (PCR),
negative hepatitis B surface antigen, availability of DNA
sample, no clinical evidence of hepatic decompensation,
no diabetes mellitus and stable cART or no need for
cART. Patients with active opportunistic infections,
active drug and/or alcohol addiction and other concomi-
tant severe diseases were excluded.
A total of 495 HIV/HCV-coinfected patients met
the inclusion criteria. Of these, DNA samples were
available for 293 patients, but only 261 patients were
available for statistical analysis: 11 patients were ex-
cluded due to DNA genotyping errors (low quantity
or quality of DNA, human and technical errors, and
so on) or having missing values. In addition, 21 patients
were excluded due to missing outcomes data. A total
of 210 patients had liver biopsy data and 178 patients
were subsequently treated with pegIFNα/RBV therapy
(Figure 1).
Figure 1 Flow chart of patients included in the genetic association analysis. BMI, body mass index; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; HOMA-IR, homeostatic model assessment-insulin resistance; pegIFNα/RBV, pegylated-interferon-alpha plus ribavirin.
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Board and the Research Ethics Committee of the
Instituto de Salud Carlos III (ISCIII). This study was
conducted in accordance with the Declaration of Helsinki
and patients gave their written informed consent for
the study.
Epidemiological and clinical data
Epidemiological and clinical data were obtained from
medical records. Body mass index (BMI) was calculated
as the weight in kilograms divided by the square of the
height in meters. The duration of HCV infection for
patients with a history of intravenous drug use (IDU)
was estimated starting from the first year they shared
needles and other injection paraphernalia, which are the
most relevant risk practices for HCV transmission [27].
For non-IDU patients, we only included those patients
for whom the initiation of their HCV infection could be
determined with certainty. The degree of insulin resist-
ance was estimated for each patient using the homeo-
static model assessment (HOMA-IR) score described
by Matthews et al. [28]: fasting glucose (mmol/l) times
fasting insulin (mU/l) divided by 22.5.
HCV assays
HCV infection was documented in all patients by
enzyme-linked immunosorbent assay (ELISA) and PCR
test. The HCV genotype was determined by hybridisation
of biotin-labeled PCR products to oligonucleotide probesbound to nitrocellulose membrane strips (INNO-LiPA
HCV II, Innogenetics, Ghent, Belgium). Plasma HCV-
RNA viral load was measured by PCR (Cobas Amplicor
HCV Monitor Test, Branchburg, NJ, USA) and real-time
PCR (COBAS AmpliPrep/COBAS TaqMan HCV test);
results were reported in terms of international units
per milliliter (IU/mL), with a lower limit of detection
of 10 IU/mL.
Liver biopsy
Liver biopsies were performed on 210 of 261 patients
following the recommendations of the Patient Care
Committee of the American Gastroenterological Associ-
ation [29]. Liver fibrosis was estimated according to the
Metavir score as follows: F0, no fibrosis; F1, portal fibrosis;
F2, periportal fibrosis or rare portal-portal septa; F3,
fibrous septa with architectural distortion; no obvious
cirrhosis (bridging fibrosis); and F4, definite cirrhosis.
Liver steatosis was evaluated according to the existence of
hepatocytes containing visible macrovesicular fat droplets.
We considered hepatic steatosis to be clinically significant
when fatty hepatocytes exceeded 10% of the hepatic
parenchyma.
Hepatitis C therapy
HCV treatment was administered to 178 of the 261
patients. Treatment regimens included pegIFNα 2a or
2b at standard doses (180 μg/week or 1.5 μg/kg/week,
respectively) plus weight-adjusted ribavirin dosing (1,000
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for patients weighing ≥75 kg). Following international
guidelines [30], patients with HCV genotypes 1 or 4
received either 48 or 72 weeks of treatment, and patients
with HCV genotype 3 were treated for 24 or 48 weeks.
Early stopping rules were applied for subjects with sub-
optimal virologic response at week 12.
Genotyping of DNA polymorphisms
Genomic DNA was extracted from peripheral blood with
a Qiagen kit (QIAamp DNA Blood Midi/Maxi; Qiagen,
Hilden, Germany). The FTO rs9939609 polymorphism
and the IFNL3 rs12980275 polymorphism were genotyped
at the Spanish National Genotyping Center (CeGen; [31])
by using the GoldenGate® assay with VeraCode® Technol-
ogy (Illumina Inc. San Diego, CA, USA).
Outcome variables
The outcome variables were: 1) metabolic disturbances:
overweight/obesity (BMI values and BMI ≥27.5 kg/m2)
and insulin resistance (HOMA-IR values and HOMA-
IR ≥2.5); 2) liver disease: significant fibrosis (F ≥2) and
steatosis (>10% fatty hepatocytes); and 3) virologic response
to HCV treatment: sustained virologic response (SVR) was
a non-detectable HCV viral load (<10 IU/mL) six months
after treatment cessation.
Statistical analysis
All statistical tests were performed with the Statistical
Package for the Social Sciences (SPSS) 19.0 software
(IBM Corp., Chicago, IL, USA). All P-values were two-
tailed and statistical significance was defined as P <0.05.
For the description of the study population, P-values
were estimated with a linear regression for continuous
variables and a Chi-square test for categorical variables.
Continuous variables were expressed as median (interquar-
tile range) and categorical variables as percentage (absolute
frequency). Hardy-Weinberg equilibrium (HWE) was as-
sessed by a Chi-square test, considering equilibrium
when P >0.05.
The genetic analysis was carried out according to
recessive and additive genetic models, but we showed
the model that best fitted the outcome variable analysed
in each case. For the genetic association study, univariate
and multivariate generalised linear models (GLM) with
normal distribution (log-link) were used to study the
association between FTO polymorphism and continuous
outcome variables (HOMA-IR and BMI). This test gives
the differences between groups and the arithmetic mean
ratio (AMR) and 95% confidence interval (95%CI). GLM
with binomial distribution (logit-link) was used to inves-
tigate the association between FTO polymorphism and
categorical outcome variables (HOMA-IR and BMI
cut-offs, liver steatosis and virologic response to HCVtherapy). This test gives the differences between groups
and the odds ratio (OR) and 95%CI. Each GLM test was
adjusted by the most significant co-variables associated
with each one of the outcome variables, avoiding over-
fitting of the regression. We included the SNP (Enter algo-
rithm) and the most relevant characteristics (Stepwise
algorithm. At each step, factors are considered for removal
or entry: a P-value for entry and exit of 0.15 and 0.20,
respectively). The covariables used were gender, age, BMI,
AIDS, nadir CD4+ T-cells, undetectable HIV viral load
(<50 copies/mL), time on cART, HCV genotype, HCV
viral load ≥500,000 IU/ml, HOMA-IR, liver fibrosis
and IFNL3 rs12980275 polymorphism. The adjusted
model also takes into consideration the combination
of specific antiretroviral drugs used by each patient,
including zidovudine, stavudine, didanosine, tenofovir,
abacavir, efavirenz, ritonavir, lopinavir, saquinavir and
fosamprenavir.
Moreover, decision tree analyses were performed via a
classification and regression tree (CART) algorithm to
classify patients according to SVR using IFNL3 and FTO
genotypes. This analysis provides a prognostic system
with a hierarchical structure based on recursive portion-
ing that builds a decision tree to identify subgroups at
higher odds of SVR. The accuracy was evaluated by cal-
culating the area under the receiver operating character-
istic curves (AUROC). The branches were pruned when
groups had fewer than 10 patients.
Results
Patient characteristics
Table 1 shows the epidemiological and clinical character-
istics of 261 non-diabetic HIV/HCV-coinfected patients.
Note that patient’s characteristics were similar when they
were stratified by FTO rs9939609 genotypes (TT, AT
and AA).
FTO polymorphism frequencies
Allele frequencies for the rs9939609 polymorphism
were 0.62 for T allele and 0.38 for A allele. Genotype
frequencies were 0.39, 0.47 and 0.14 for TT, TA, AA
genotypes, respectively. These frequencies in our data-
set were in accordance with the data listed on the
National Center for Biotechnology Information (NCBI)
SNP database [32]. The rs9939609 SNP fulfilled the
minimum allele frequency (MAF) >0.05 for all sam-
ples and displayed less than 5% of missing values.
Furthermore, rs9939609 polymorphism was in HWE
(P = 0.999).
FTO polymorphism, metabolic disturbances and liver disease
Table 2 shows the relationship between the metabolic
disturbances and the rs9939609 polymorphism under a
model of recessive inheritance, which was the genetic
Table 1 Clinical and epidemiological characteristics of all HIV/HCV-coinfected patients stratified by FTO genotype
Characteristics All patients (number = 261) TT (number = 101) AT (number = 123) AA (number = 37) P-value
Gender (male) 74.7% (195) 73.3% (74) 74% (91) 81.1% (30) 0.625
Age (years) 40.9 (6.9) 40.6 (6.17) 41.1 (7.69) 42.1 (6.6) 0.849
HIV acquired by IVDU 85.4% (223) 85.1% (86) 83.7% (103) 91.9% (34) 0.556
Years since HCV infection 21 (8.4) 21.3 (8.35) 20.9 (8.25) 21.6 (7.8) 0.670
Prior AIDS 29.1% (76) 69.3% (70) 74.8% (92) 37.8% (14) 0.302
cART 84.7% (221) 82.2% (83) 87.8% (108) 81.1% (30) 0.410
Time on cART (years) 4.8 (5) 4.6 (4.9) 5 (4.8) 4.7 (5.1) 0.350
Current cART protocols
Any NRTIs + any PI 24.5% (64) 25.7% (26) 25.2% (31) 18.9% (7) 0.691
Any NRTIs + PI + NNRTI 1.1% (3) 1% (1) 1.6% (2) 0% (0) 0.705
Any NRTIs + any NNRTI 51.3% (134) 50.5% (51) 51.2% (63) 54.1% (20) 0.933
Only NRTIs 7.3% (19) 5% (5) 9.8% (12) 5.4% (2) 0.346
Specific antiretroviral drugs
Zidovudine 27.2% (71) 25.7% (26) 30.1% (37) 21.6% (8) 0.547
Stavudine 26.1% (68) 24.8% (25) 28.5% (35) 21.6% (8) 0.659
Didanosine 16.9% (44) 18.8% (19) 13.8% (17) 21.6% (8) 0.431
Tenofovir 26.8% (70) 28.7% (29) 22% (27) 37.8% (14) 0.138
Abacavir 16.1% (42) 9.9% (10) 21.1% (26) 16.2% (6) 0.075
Efavirenz 30.3% (79) 29.7% (30) 30.1% (37) 32.4% (12) 0.951
Ritonavir (r) 6.1% (16) 5.9% (6) 7.3% (9) 2.7% (1) 0.588
Lopinavir/r 12.3% (32) 10.9% (11) 12.2% (15) 16.2% (6) 0.700
Saquinavir 1.1% (3) 0% (0) 1.6% (2) 2.7% (1) 0.332
Fosamprenavir 2.3% (6) 3% (3) 2.4% (3) 0% (0) 0.582
HIV markers
Nadir CD4+ T-cells (cells/μL) 204 (223) 210 (262) 195 (221) 210 (201) 0.157
Nadir CD4+ <200 cells/μL 49% (128) 46.5% (47) 52% (64) 45.9% (17) 0.658
CD4+ T cells/μL 465 (325) 460 (435) 472 (234) 456 (251) 0.313
CD4+ ≥500 cells/μL 43.5% (113) 55.4% (56) 57.4% (70) 43.2% (16) 0.959
HIV-RNA <50 copies/mL 76.9% (200) 75% (75) 78% (96) 78.4% (29) 0.844
HCV markers
HCV-genotype 1/4 73.4% (185) 68.8% (66) 75% (90) 80.6% (29) 0.339
HCV-RNA ≥500,000 UI/ml 75.1% (187) 29.6% (29) 23.5% (27) 83.3% (30) 0.275
IFNL3 rs12980275 (AA) 47.5% (122) 47.5% (48) 50% (61) 38.2% (13) 0.557
Categorical variables are expressed in percentage (absolute count).; continuous variables are expressed in median (interquartile range) P-values were estimated
with Chi-square test for categorical variable and linear regression test for continuous variable. AIDS, acquired immunodeficiency syndrome; cART, combination
antiretroviral therapy; HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV, human immunodeficiency virus; HIV-RNA, HIV plasma viral load; IVDU, intravenous
drug users; NNRTI, no nucleoside analog reverse-transcriptase inhibitors; NRTI, nucleoside analog reverse-transcriptase inhibitors; PI, protease inhibitors.
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by homozygous for the minor A allele is increased r-fold
in comparison to the rest (TT and AT genotypes).
Patients with the rs9939609 AA genotype had higher
values of BMI (P = 0.016) and HOMA-IR (P = 0.003)
than patients with the rs9939609 AT/TT genotype. Also,
the rs9939609 AA genotype had a higher percentage of
patients with BMI ≥27.5 kg/m2 (P = 0.011), HOMA-IR ≥2.5(P = 0.040) and significant fibrosis (P = 0.049) than
rs9939609 AT/TT. When the multivariate regression
analyses were performed, we found that the rs9939609
AA genotype was associated with higher values of BMI
(adjusted AMR (aAMR) = 1.08; P = 0.002) and HOMA-IR
values (aAMR = 1.32; P = 0.027), and higher likeli-
hoods of achieving values of BMI ≥27.5 kg/m2 (adjusted
OR (aOR) = 3.46; P = 0.024), HOMA-IR ≥2.5 (aOR = 2.09;
Table 2 Relationship between rs9939609 polymorphism
Outcomes All patients TT AT AA P-value(a) aAMR (95%CI) P-value(b)
Continuous variables
BMI (kg/m2) 23.29 ± 0.25 22.69 ± 0.35 22.91 ± 0.32 24.29 ± 0.58 0.016 1.08 (1.03; 1.14) 0.002
HOMA-IR 3.24 ± 0.19 2.97 ± 0.29 2.75 ± 0.26 4.19 ± 0.47 0.003 1.32 (1.03; 1.69) 0.027
All patients TT AT AA P-value(a) aOR (95%CI) P-value(b)
Categorical variables
Overweight (BMI ≥27.5 kg/m2) 8.5% (22/260) 4% (4/100) 8.9% (11/123) 19.4% (7/36) 0.011 3.46 (1.17; 10.21) 0.024
HOMA-IR ≥2.5 41.4% (108/261) 38.6% (39/101) 39% (48/123) 56.8% (21/37) 0.040 2.09 (1.02; 4.32) 0.045
Significant fibrosis (F≥ 2) 48.6% (102/210) 48.8% (41/84) 43.3% (42/97) 65.5% (19/29) 0.049 2.34 (1.02; 5.36) 0.045
Steatosis (>10% fatty hepatocytes) 56.9% (115/202) 51.9% (41/79) 57% (53/93) 70% (21/30) 0.117 3.65 (1.29;10.36) 0.015
aP-values were calculated by Chi-square tests for categorical variables and generalized linear models (GLM) with normal distribution (log-link) for continuous
variables; bP-values were calculated by GLM adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section). Metabolic
disturbances and liver disease in HIV/HCV-coinfected patients. Categorical variables are expressed in percentage (absolute count) and continuous variables are
expressed in estimated marginal mean ± standard error of the mean. Statistically significant differences are shown in bold. 95%CI, 95% confidence interval; aAMR,
adjusted arithmetic mean ratio; aOR, adjusted odds ratio; BMI, body mass index; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HOMA-IR, homeostatic
model assessment-insulin resistance.
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steatosis (aOR = 3.65; P = 0.015).
Additional file 1: Tables S1 and S2 show the analyses
stratified by HCV-GT1 and HCV-GT3, respectively. For
HCV-GT1 patients, the rs9939609 AA genotype was
only linked to HOMA-IR (aAMR = 1.52; P = 0.017).
With regard to HCV-GT3 patients, the rs9939609 AA
genotype was associated with elevated BMI values
(aAMR = 1.18; P = 0.004).
FTO polymorphism and virologic response to HCV treatment
Table 3 shows the relationship between the rs9939609
polymorphism and the virologic responses to HCV treat-
ment under an additive model of inheritance. Therefore,
the risk conferred by an allele is increased r-fold for het-
erozygotes and 2r-fold for homozygotes with two copies
of a specific allele.
We analyzed 178 of 261 patients who were treated
with pegIFNα/RBV. The number of patients who failed
to complete HCV therapy was 16 (12 adverse events
and 4 abandonments) and 162 patients had a full course
of HCV therapy. In an intention-to-treat analysis, the SVR
rate was 55.1%, which decreased with each minor A allele
at rs9939609 (P = 0.026). Additionally, the multivariate
analysis revealed similar results, showing that rs9939609Table 3 Relationship between rs9939609 polymorphism and v
patients according to HCV genotypes
HCV genotype All patients TT AT
All patients 55.1% (98/178) 64.3% (45/70) 51.8% (43/83)
GT2/3 patients 85.5% (47/55) 92.0% (23/25) 83.3% (20/24)
GT1/4 patients 40.7% (48/118) 48.8% (20/41) 37.9% (22/58)
aP-values were calculated by linear-by-linear association Chi-squared test; bP-values
the most important clinical and epidemiological characteristics (see Statistical analy
confidence interval; aOR, adjusted odds ratio; GT1/4, HCV genotype 1/4; GT2/3, HCV
SVR, sustained virologic response.A allele decreased the likelihood of achieving SVR
(aOR = 0.58; P = 0.044).
A decision tree was also performed using both
rs12980275 and rs9939609 polymorphisms (Figure 2).
For GT1/4 patients, the SVR rate decreased from 41.5%
to 33.8% in patients with the rs12980275 AG/GG geno-
type and then to 25.5% in patients with the rs9939609
AT/AA genotype while it increased to 48.1% in patients
with the rs9939609 TT genotype. For GT2/3 patients, the
SVR rate decreased from 83.9% to 77.4% in patients with
the rs9939609 AT/AA genotype while it increased to
92.0% in patients with the rs9939609 TT genotype. The
overall percentage of patients correctly classified (accur-
acy) was 68.2% and the AUROC of this decision tree was
0.766 (95%CI = 0.696; 0.835. P <0.001). Furthermore, this
analysis was replicated considering the HCV-GT1 and
HCV-GT3 separately (Additional file 1: Table S1 and
Figure S1), finding similar results to those previously
described (Figure 2).
Discussion
The association between the FTO rs9939609 polymor-
phism and metabolic factors is well documented in the
general population [19,22-24]. However, to the best of
our knowledge, this is the first description of the relationirologic responses to HCV treatment in HIV/HCV-coinfected
AA P-value(a) aOR (95%CI) P-value(b)
40.0% (10/25) 0.026 0.58 (0.34; 0.99) 0.044
66.7% (4/6) 0.125 0.43 (0.14; 1.31) 0.138
31.5% (6/19) 0.171 0.59 (0.31; 1.12) 0.105
were calculated by multivariate generalized linear models (GLM) adjusted by
sis section). Statistically significant differences are shown in bold. 95%CI, 95%
genotype 2/3; HCV, hepatitis C virus; HIV, human immunodeficiency virus;
Figure 2 Flowchart of the decision tree for sustained virologic responses (SVR) in HIV patients coinfected with HCV. Nodes have been
stratified by HCV-GT (1/4 versus 2/3), IFNL3 rs12980275 (AA versus AG/GG) and FTO rs9939609 (TT versus AT/AA) polymorphisms. HCV-GT, hepatitis
C virus genotype.
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bolic disturbances in HIV/HCV-coinfected patients. In
this study, we showed that patients with an rs9939609
AA genotype had increased odds of obesity, insulin
resistance, significant fibrosis and liver steatosis; and
the presence of the risk A allele (both AA and AT
genotypes) was associated with a lower response rate
to pegIFNα/ribavirin therapy. This effect does not appear
to be dependent on the HCV genotype, although we could
not confirm this with certainty due to a lack of statistical
power when we performed the analysis stratified by
HCV genotype.
Obesity is a complex metabolic disturbance in which
genetic and environmental factors may interact to produce
homeostatic abnormalities [21], but in addition, both the
HIV/HCV coinfection and the cART also influence the
development of other comorbidities, such as insulin resist-
ance and steatosis [7]. Recent meta-analyses have reliably
established that FTO rs9939609 is robustly associated
with increased BMI and adiposity across different ages
and populations [22,33]. Evidence to date suggests thatthe association between rs9939609 and BMI is predo-
minantly driven by an increased energy intake, and that
patients with the rs9939609 AA genotype exhibit overall
increased ad libitum food-intake and impaired satiety
[34-37]. In our study, subjects homozygous for the
‘obesity-risk’ A allele also had an increased risk for
overweight/obesity (both continuous BMI values and
BMI ≥27.5 kg/m2) compared with carriers of the low-
risk T allele. Nevertheless, we must not discount the
fact that our patients had a relatively low BMI (only 6.5%
of patients were overweight), possibly due to the fact that
around 85% of them were IDUs. The HIV infection and
chronic drug abuse both compromise the nutritional sta-
tus of patients despite major advances in HIV treatment
[38], allowing that HIV-positive IDUs had lower BMIs.
The relationship between HCV and obesity is clinically
relevant due to the potential synergism on liver disease
severity and the multifaceted interactions between HCV
and glucose metabolism [26]. HCV infection is able
to perturb glucose homeostasis through several direct
and indirect mechanisms, leading to both hepatic and
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http://www.biomedcentral.com/1741-7015/12/198extrahepatic insulin resistance [26], which accelerates
liver disease progression (development of steatosis, fibro-
sis and hepatocellular carcinoma), reduces response to
HCV antivirals, and increases the risk of developing type 2
diabetes mellitus [26]. However, the mechanisms by which
CHC leads to insulin resistance are not fully understood.
There is growing evidence that DNA polymorphisms may
contribute to differences in complex disease traits between
individuals. In this setting, many studies have investigated
the relationship of the FTO rs9939609 polymorphism with
insulin resistance and type 2 diabetes mellitus in the
general population (HIV and HCV seronegative subjects)
[19,24,39-41]. According with this, our study revealed that
coinfected patients carrying the rs9939609 AA genotype
had higher HOMA-IR values and a frequency of HOMA-
IR ≥2.5 than patients carrying the rs9939609 AT/TT geno-
type. However, our data revealed that the FTO rs9939609
polymorphism was not associated with HOMA-IR ≥3.0
and HOMA-IR ≥3.8 (data not shown), possibly due to the
limited sample size, since a near-significant trend was
observed. Moreover, this lack of association could be
due to the possible distortive effect of direct and in-
direct factors related to both HIV and HCV infections,
and cART [7].
Liver steatosis is a frequent finding in CHC (≥40%
cases). In HCV infection with GT3, viral factors are im-
plicated in the development of steatosis via activation of
de novo lipogenesis, while for HCV infection with GT1
or GT4, metabolic host factors, such as obesity and insu-
lin resistance, provide an increased risk of steatosis [26].
Additionally, oxidative damage induced by the HCV core
protein may simultaneously induce steatosis and impair
insulin signaling in the hepatocyte [26]. The FTO gene is
highly expressed in the hypothalamus and pancreatic
islets, and it is found in other tissues such as adipose
tissue, liver, and skeletal muscle. The FTO over-expression
level seems to be related to subcutaneous fat accu-
mulation [42], obesity [43] and oxidative stress and lipid
deposition in the liver [44]. Furthermore, the rs9939609
AA genotype exhibits increased FTO expression com-
pared with the TT genotype [35]. In our study, the
rs9939609 AA genotype was related to higher likelihoods
of steatosis, a finding that is consistent with the rela-
tionship found between rs9939609, obesity and insulin
resistance in these same patients. This fact could have
important clinical implications because persistent fatty
liver disease may be a problem for patients even with
successful HCV clearance [45,46].
Our analysis also shows that the rs9939609 polymorph-
ism was associated with increased odds of significant liver
fibrosis. Considering that the development of liver fibrosis
is strongly associated with overweight/obesity, insulin
resistance and steatosis [7,47,48], we think that the associ-
ation between the FTO rs9939609 polymorphism and liverfibrosis might be mediated by the metabolic disorders
related to CHC.
Considering all the factors discussed above, it could be
possible that the FTO rs9939609 polymorphism might
be related to response to HCV therapy through regulating
obesity, insulin resistance and liver steatosis in CHC
patients [26]. In our study, the rs9939609 A risk-allele
showed an inverse significant association with SVR.
These associations remained after adjusting for the most
important predictive factors related to HCV treatment
response, such as IFNL3 genotype, HOMA-IR, HCV
genotype, HCV-RNA viral load, and so on [13]. How-
ever, when patients were stratified by HCV genotype,
the trends were maintained but were not statistically
significant, possibly due to the limited sample size. In
any case, we did not observe an association that could
be dependent on HCV genotype. Moreover, we made an
algorithm based on the genotypes of HCV, IFNL3 and
FTO, finding that the FTO genotype was able to improve
the classification into responder and non-responder to
pegIFNα/ribavirin therapy for difficult-to-treat patients
(GT1/4) with an unfavourable IFNL3 genotype (rs12980275
AG/GG). Moreover, the classification of GT2/3 patients
also improved without the assistance of the IFNL3
genotype. In this case, the rs12980275 genotype was not
included in the GT2/3 decision tree due to two main
reasons: 1) For a decision tree analysis, the sample size
in the GT2/3 group (56 patients) was quite limited to
obtain valid results; and thus, the second node was
pruned because it had fewer than 10 patients. 2) IL28B
SNPs are not been useless for predicting HCV therapy
outcome in HIV/HCV-coinfected patients infected with
HCV-GT2/3 [49]. This fact is may be due to the high
SVR rate found in these IFN-sensitive genotypes, where
a larger sample size would be required to establish sta-
tistical differences [50]. Thus, the FTO rs9939609 poly-
morphism might provide a new clinical value in patients
who have no access to newer DAAs treatment.
To date, many articles have assessed the influence
of IL28B polymorphisms on SVR in CHC patients,
rs12979860, rs8099917, and rs12980275 being the most
studied [51]. These IL28B polymorphisms are being used
as predictive markers of response to pegIFNα/RBV therapy
in clinical practice, especially in patients with HCV geno-
types 1 and 4 [13]. Although rs12979860 is more likely to
be correlated with SVR in the European white population,
we have recently shown a strong association of rs12980275
and rs8099917 with SVR in HCV/HIV-coinfected patients
[52]. In the current study, we analyzed rs12980275, which
is also in high linkage disequilibrium with rs8099917 and
rs12979860 in the European population [50]. In addition,
rs12980275 has been less studied than rs12979860 in
European white populations, and, therefore, additional
results involving rs12980275 would be of interest.
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response rate [17]. This fact might obscure the influence
on treatment efficacy of IFNL3 polymorphisms and
other SNPs, such as the FTO rs9939609 polymorphism.
However, some authors have still suggested that the
IFNL3 genotype plays a key role for certain IFN-free reg-
imens since several clinical trials have revealed an asso-
ciation between IFNL3 polymorphisms and treatment
efficacy [53]. Moreover, the role of tools for making pre-
treatment decisions may still be relevant since DAAs are
more expensive and carry a higher risk for side effects,
while decision-making based on IFNL3 polymorphisms
and other SNPs might permit non-DAA-based treatment
algorithms. Finally, it should also be borne in mind that
few data are available in HIV/HCV coinfected patients
about the interaction of IFN-free regimens and metabolic
disturbances, where FTO is a cornerstone. Thus, fur-
ther analysis will be needed to determine whether
FTO rs9939609 polymorphism could provide additional
information to select patients with better or worse re-
sponse to HCV treatment.
There are some issues that have to be considered for a
correct interpretation of our data:
Firstly, this report has a cross-sectional design (ana-
lysis of metabolic disturbances) and a retrospective design
(analysis of virological response to HCV therapy), both
with a relatively small number of patients, which could
limit the achievement of significant values between the
rs9939609 polymorphism and the outcome variables (for
example: BMI ≥25 kg/m2, HOMA-IR ≥3.0, HOMA-
IR ≥3.8, HCV-therapy response according to HCV
genotype, and so on). In addition, our cohort had a
population with mixed HCV genotypes (1, 2, 3 and 4),
which complicates the interpretation of the data since, for
example, GT1 and GT3 did not have exactly the same
pathophysiology and response to HCV treatment.
Secondly, metabolic disturbances are caused by several
interacting genetic and environmental determinants,
making it complicated to find the true individual effects
of each disease-associated factor. In this regard, we
did not have data on some extra factors that may
have an influence on lipid levels and insulin resist-
ance, such as exercise habits, diet, lipodystrophy, and
alcohol intake.
Thirdly, the patients selected for our study were pa-
tients who met a set of criteria for starting HCV treat-
ment (for example, no alcohol abuse, high CD4 cell
counts, controlled HIV replication and good treatment
adherence), and it is possible that this may have intro-
duced a selection bias. Furthermore, HCV therapy regi-
mens were not identical since they varied in some
characteristics, such as pegIFNα 2a or 2b and likely
ribavirin dose. Instead, each physician administered
the appropriate HCV therapy regimen according to his/hercriteria and by following local and/or international
guidelines.
Fourthly, we did not study any cohort of HCV-
monoinfected patients in order to evaluate the influence
of the FTO rs9939609 polymorphism on CHC without
the presence of HIV infection. In addition, we did not
study any cohort of HIV-monoinfected patients in order
to evaluate the influence of the FTO rs9939609 poly-
morphism on the development of metabolic disturbances
with the presence of HIV infection and cART. Moreover,
since the study was carried out entirely in white Europeans,
and the frequency of these alleles differs among different
ethnicities, it would be necessary to perform an independ-
ent replication of this study for different ethnic groups.
Fifthly, we evaluated several outcome variables and
could raise the need to adjust the ‘P-value’. However, we
think that it is not necessary to adjust the ‘P-value’ after
multiple tests on clinical-orientated studies [54,55], be-
cause: 1) the outcome variables cannot be considered
completely independent; 2) there was a hypothesis sup-
ported by theory and we were not doing a random search
of a meaningful result; and 3) our results had a clear inter-
pretation. Thus, our results, which always pointed in the
same direction, should not be ruled out. However, we
should not overlook the level of uncertainty of these data.
Conclusions
Our study shows the first evidence that HCV/HIV-coin-
fected patients carrying the unfavourable A allele of the
FTO rs9939609 polymorphism had higher odds of meta-
bolic disturbances and lower likelihoods of achieving a
successful virologic response to HCV therapy. Further
analyses are needed to determine the potential use of
the rs9939609 polymorphism as a predictive marker of
metabolic disturbances and HCV therapy response.
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